This study used retrospective chart review and survey data to evaluate: (1) did not know whether they received the PAC. A total of 72.4% of patients reported that they were unaware that some patients receiving rituximab experience PML. A higher proportion of PAC recipients identified PML as a potential risk of rituximab than nonrecipients (37.8% vs 19.9%); 58.3% of PAC recipients had poor awareness of PML. Most PAC recipients (90.0%) and nonrecipients (85.5%) correctly answered that they should seek medical attention for infection symptoms. In conclusion, approximately 30% of patients received off-label rituximab. Most patients reported not receiving the PAC or having knowledge of PML but demonstrated understanding of the recommended action in the event of infection symptoms, regardless of PAC receipt.
The purpose of the PAC is to inform the patient of the need for vigilance with respect to PML and other infections generally.
Furthermore, the objective of the PAC is to ensure that patients seek medical attention early and that HCPs are aware of the need for timely and appropriate measures to diagnose PML. The rationale is that, with a timely diagnosis of PML or infection, treatment with rituximab could be discontinued and reductions or discontinuation of concomitant immunosuppressive therapy considered. Reconstitution of the immune system in immunocompromised patients with PML has resulted in stabilization or improved outcome. 10 Whether early detection of PML and suspension of rituximab therapy may lead to similar stabilization or improved outcome is unknown.
2,11
The aims of this study were: (1) to quantify and characterize off-label use of rituximab by evaluating the medical records of patients treated with rituximab for nononcology conditions, and (2) to use survey data to assess the extent to which patients receive and read the PAC, their knowledge of the PAC content, and whether distribution of the PAC might influence patient actions. from a period of 12 months prior to index date were retrospectively reviewed and abstracted ( Figure 1 ). This "look-back period" from June 2014 to June 2015 was used to ensure that data collected were fully reflective of the real-world administration of rituximab and not influenced by study awareness. The observation period corresponded to the interval between the first and last infusion dates of rituximab, if treatment was discontinued before the index date. If the patient was still receiving rituximab at the index date, then the observation period was the interval between the first infusion date and the index date.
| MATERIAL S AND ME THODS

| Medical record data collection to determine off-label use
This study was conducted in accordance with all applicable ethical and regulatory requirements, including the Declaration of Helsinki. Approval from each relevant ethics committee was obtained prior to the study start in each country and documented in a letter to the center specifying the date on which the ethics committee granted approval. All patients provided informed consent for participation in the medical records data collection and/or survey.
| Patient Alert Card survey
Patients aged ≥ 18 years receiving rituximab for a nononcology indica- receipt and review of the PAC, and any actions the patient would take or had taken as a result of receiving the PAC.
| Safety
Individual adverse event (AE) information captured during the survey was reported to Roche as the Marketing Authorization Holder (MAH).
| Statistical analysis
Analyses of both rituximab off-label use (for indications other than RA or GPA/MPA; the pemphigus vulgaris indication was not approved at the time of this study) and the evaluation of patient receipt and knowledge of the PAC were descriptive in nature and included summary statistics and the frequency distribution of item responses. No statistical testing was performed; however, 95% CIs of the proportions of patients receiving rituximab for approved and off-label uses were calculated to assess precision of the prevalence estimates. Missing data were not imputed, and the data were analyzed and presented as recorded. patients (32.8%) reported they received the PAC, 302 (59.3%) reported they did not receive the PAC, and 40 (7.9%) did not know whether they had received the PAC (Figure 2 ). Among patients who reported receiving the PAC and answered the following questions, 111/155 (71.6%) responded that they received the PAC only the first time they received a rituximab infusion, 81/157 (51.6%) reported that they received an explanation of the PAC content from a doctor or nurse other than the doctor who prescribed rituximab, and 125/157 (79.6%) reported they had read the PAC (Figure 2 ).
| RE SULTS
| Medical records data for off-label use
| Patient Alert Card survey
Only 124/497 patients (24.9%) reported that they were aware that, very rarely, some patients being treated with rituximab experience PML ( Figure 3 
| Safety
| Limitations
Findings of this study largely pertain to the infusion centers involved in routine rheumatological practice that predominantly (≈80%) participated in this study; therefore, certain off-label conditions not primarily treated in routine rheumatology practice (eg, some dermatologic or ophthalmologic conditions) were unlikely to be captured in this study.
As is the case with all voluntary surveys, invited patients self-selected into the survey component of the study, and thus selection Furthermore, patients' answers to the survey may have been influenced by when they received the PAC and their ability to recall the information contained in the PAC. For example, 71.6% of patients reported receiving the PAC only the first time they received a rituximab infusion, and only 12.9% of patients reported that they received the PAC every time they received a rituximab infusion. Therefore, if patients had not received the PAC when they arrived at the clinic (the survey was administered after arrival but before the infusion) but had received it at their last infusion (weeks to months previously), they may not recall if they had received the PAC or the information it contained.
Finally, all analyses were descriptive, with no correlations noted or statistical significance tests performed; therefore, it is not possible to confirm an association between PAC receipt and a greater understanding of the risks of PML and other infections.
Results of this study demonstrated that in nononcology condi- 
E TH I C S S TATEM ENT
This study was conducted in accordance with all applicable ethical and regulatory requirements, including the Declaration of Helsinki. Approval from each relevant ethics committee was obtained prior to the study start in each country and documented in a letter to the center specifying the date on which the ethics committee granted approval. All patients provided informed consent for participation in the medical records data collection and/ or survey.
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